Colchicine, an anti-rheumatic agent, as a potential compound for the treatment of COVID-19
1
Rheumatology Unit, Department of Medicine, University of Perugia, Italy
Online publication date: 2021-09-08
Reumatologia 2021;(Konferencja Pacjent post-COVID-owy. Co zostaje, a co się zmienia? 1):261-264
ABSTRACT
The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has swept the world in a pandemic. The disease (COVID-19) is characterized by acute respiratory distress, and there is an immediate need for any effective agent before the development of a vaccine. Coronavirus-19 disease (COVID-19) is an infectious disease caused by SARS-CoV-2, a -coronavirus which causes pneumonia, requires intensive care unit hospitalization in about 10% of cases and can lead to a fatal outcome [1].
REFERENCES (25)
1.
Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? Lancet 2020; 395: 1225-1228, DOI: 10.1016/S0140-6736(20)30627-9.
2.
Stebbing J, Phelan A, Griffin I, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis 2020; 20: P400-402, DOI: 10.1016/S1473-3099(20)30132-8.
3.
Perricone C, Triggianese P, Bartoloni E, et al. The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19. J Autoimmun 2020; 111: 102468, DOI: 10.1016/j.jaut.2020.102468.
4.
Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol 2020; 20: 355-362, DOI: 10.1038/s41577-020-0331-4.
5.
Risitano AM, Mastellos DC, Huber-Lang M, et al. Complement as a target in COVID-19? Nat Rev Immunol 2020; 20: 343-344, DOI: 10.1038/s41577-020-0320-7.
6.
Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J Heart Lung Transplant 2020; 39: 405-407, DOI: 10.1016/j.healun.2020.03.012.
7.
Martinon F, Pétrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440: 237-441, DOI: 10.1038/nature04516.
8.
Nuki G. Colchicine: its mechanism of action and efficacy in crystal-induced inflammation. Curr Rheumatol Rep 2008; 10: 218-227, DOI: 10.1007/s11926-008-0036-3.
9.
Apostolidou E, Skendros P, Kambas K, et al. Neutrophil extracellular traps regulate IL-1-mediated inflammation in familial Mediterranean fever. Ann Rheum Dis 2016; 75: 269-277, DOI: 10.1136/annrheumdis-2014-205958.
10.
Richter M, Boldescu V, Graf D, et al. Synthesis, biological evaluation, and molecular docking of combretastatin and colchicine derivatives and their hCE1-Activated Prodrugs as antiviral agents. ChemMedChem 2019; 14: 469-483, DOI: 10.1002/cmdc. 201800641.
11.
Biswas K, Das Sarma J. Effect of microtubule disruption on neuronal spread and replication of demyelinating and nondemyelinating strains of mouse hepatitis virus in vitro. J Virol 2014; 88: 3043-3047, DOI: 10.1128/JVI.02545-13.
12.
Lu N, Yang Y, Liu H, et al. Inhibition of respiratory syncytial virus replication and suppression of RSV-induced airway inflammation in neonatal rats by colchicine. Biotech 2019; 9: 392, DOI: 10.1007/s13205-019-1917-z.
13.
Worachartcheewan A, Songtawee N, Siriwong S, et al. Rational design of colchicine derivatives as anti-HIV agents via QSAR and molecular docking. Med Chem 2019; 15: 328-340, DOI: 10.2174/1573406414666180924163756.
14.
Chen IY, Moriyama M, Chang MF, Ichinohe T. Severe acute respiratory syndrome coronavirus viroporin 3a activates the NLRP3 inflammasome. Front Microbiol 2019; 10: 50, DOI: 10.3389/fmicb.2019.00050.
15.
Channappanavar R, Perlman S. Evaluation of activation and inflammatory activity of myeloid cells during pathogenic human coronavirus infection. Methods Mol Biol 2020; 2099: 195-204, DOI: 10.1007/978-1-0716-0211-9_15.
16.
Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis 2020; 71: 762-768, DOI: 10.1093/cid/ciaa248.
17.
Elshafei MN, Khalil A, El-Bardissy A, et al. The efficacy of colchicine in the management of coronavirus disease 2019: a protocol for systematic review and meta-analysis. Medicine (Baltimore) 2020; 99: e21911, DOI: 10.1097/MD.0000000000021911.
18.
Della-Torre E, Ramirez GA, Dagna L, Tresoldi M. Colchicine treatment in community healthcare setting to prevent severe COVID-19. Ann Rheum Dis 2020, DOI: 10.1136/annrheumdis- 2020-218759 [Epub ahead of print].
19.
Piantoni S, Colombo E, Furloni R, et al. Anti-inflammatory action of colchicine in hospitalised patients with COVID-19. Response to: ‘Colchicine treatment in community healthcare setting to prevent severe COVID-19’ by Della-Torre et al. Ann Rheum Dis 2020, DOI: 10.1136/annrheumdis-2020-218806 [Epub ahead of print].
20.
Papadopoulos C, Patoulias D, Teperikidis E, et al. Colchicine as a potential therapeutic agent against cardiovascular complications of COVID-19: an exploratory review. SN Compr Clin Med 2020: 1-11, DOI: 10.1007/s42399-020-00421-x [Epub ahead of print].
21.
Schlesinger N, Firestein BL, Brunetti L. Colchicine in COVID-19: an old drug, new use. Curr Pharmacol Rep 2020: 1-9, DOI: 10.1007/s40495-020-00225-6 [Epub ahead of print].
22.
Scarsi M, Piantoni S, Colombo E, et al. Association between treatment with colchicine and improved survival in a single- centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome. Ann Rheum Dis 2020; 79: 1286-1289, DOI: 10.1136/annrheumdis-2020-217712.
23.
Mansouri N, Marjani M, Tabarsi P, et al. Successful treatment of Covid-19 associated cytokine release syndrome with colchicine. A case report and review of literature. Immunol Invest 2020: 1-7, DOI: 10.1080/08820139.2020.1789655 [Epub ahead of print].
24.
Gandolfini I, Delsante M, Fiaccadori E, et al. COVID-19 in kidney transplant recipients. Am J Transplant 2020; 20: 1941-1943, DOI: 10.1111/ajt.15891.
25.
Deftereos SG, Giannopoulos G, Vrachatis DA, et al. Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: the GRECCO-19 randomized clinical trial. JAMA Netw Open 2020; 3: e2013136, DOI: 10.1001/jamanetworkopen.2020.13136.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
